Hernandez, C.; Arasanz, H.; Chocarro, L.; Bocanegra, A.; Zuazo, M.; Fernandez-Hinojal, G.; Blanco, E.; Vera, R.; Escors, D.; Kochan, G.
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. Int. J. Mol. Sci. 2020, 21, 2411.
https://doi.org/10.3390/ijms21072411
AMA Style
Hernandez C, Arasanz H, Chocarro L, Bocanegra A, Zuazo M, Fernandez-Hinojal G, Blanco E, Vera R, Escors D, Kochan G.
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences. 2020; 21(7):2411.
https://doi.org/10.3390/ijms21072411
Chicago/Turabian Style
Hernandez, Carlos, Hugo Arasanz, Luisa Chocarro, Ana Bocanegra, Miren Zuazo, Gonzalo Fernandez-Hinojal, Ester Blanco, Ruth Vera, David Escors, and Grazyna Kochan.
2020. "Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies" International Journal of Molecular Sciences 21, no. 7: 2411.
https://doi.org/10.3390/ijms21072411
APA Style
Hernandez, C., Arasanz, H., Chocarro, L., Bocanegra, A., Zuazo, M., Fernandez-Hinojal, G., Blanco, E., Vera, R., Escors, D., & Kochan, G.
(2020). Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. International Journal of Molecular Sciences, 21(7), 2411.
https://doi.org/10.3390/ijms21072411
